Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod

Arch Dermatol. 2002 Sep;138(9):1137-9. doi: 10.1001/archderm.138.9.1137.

Authors

Karen Rebecca Suchin¹, Jacqueline M Junkins-Hopkins, Alain H Rook

Affiliation

¹ Department of Dermatology, Hospital of the University of Pennsylvania, 2 Rhoads Pavilion, 3600 Spruce St, Philadelphia, PA 19104-2399, USA. arook@mail.med.upenn.edu

PMID: 12224972
DOI: 10.1001/archderm.138.9.1137

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adjuvants, Immunologic / administration & dosage*
Administration, Topical
Aminoquinolines / administration & dosage*
Biopsy, Needle
Female
Follow-Up Studies
Humans
Imiquimod
Immunohistochemistry
Lymphoma, T-Cell, Cutaneous / diagnosis
Lymphoma, T-Cell, Cutaneous / drug therapy*
Lymphoma, T-Cell, Cutaneous / pathology*
Middle Aged
Neoplasm Staging
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology*
Treatment Outcome

Substances

Adjuvants, Immunologic
Aminoquinolines
Imiquimod